Company intelligence / Profile preview

ClostraBio

Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

ClostraBio published breakthrough research in Nature Biomedical Engineering demonstrating that polymeric nanoscale micelles can effectively restore intestinal homeostasis in mouse models of colitis and peanut allergy. CLB101™, the company's lead ingredient, completed toxicology studies published in the International Journal of Toxicology with GRAS (Generally Recognized as Safe) designation. CLB101™ launched commercially in September 2025 through a healthcare practitioner-focused dietary supplement partner.

Therapeutic areas: ImmunologyGastroenterology
Modalities: Live biotherapeutic product therapyNanoparticlePolymer-drug conjugate therapy
Industry: Biotech

Drug pipeline

2 assets

CLB-004

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Portal Innovations

Beyond the preview

Go deeper on ClostraBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ClostraBio.

Explore the full profile